C-reactive protein is an acute phase reactant synthesized. C-Reactive Protein and Coronary Events Following Percutaneous Coronary Angioplasty
|
|
- Philippa Knight
- 6 years ago
- Views:
Transcription
1 CLINICAL STUDIES and Coronary Events Following Percutaneous Coronary Angioplasty Robbert J. de Winter, MD, PhD, Karel T. Koch, MD, PhD, Jan P. van Straalen, Gerlind Heyde, MD, Matthijs Bax, MD, Carl E. Schotborgh, MD, Karla J. Mulder, Gerard T. Sanders, PhD, Johan Fischer, PhD, Jan G. P. Tijssen, PhD, Jan J. Piek, MD, PhD PURPOSE: We investigated the associations between baseline C-reactive protein levels in patients undergoing percutaneous coronary angioplasty and death, nonfatal myocardial infarction, and repeat revascularization during 14 months of followup. METHODS: In a single-center, prospective, cohort study, plasma levels of C-reactive protein were measured in 1458 consecutive patients undergoing elective or urgent coronary angioplasty. Patients were followed at 12 to 14 months for the occurrence of death, nonfatal myocardial infarction, and repeat revascularization. RESULTS: The incidence of death or myocardial infarction was 6.1% (44/716) in patients with an increased C-reactive protein level () and 1.5% (11/742) in patients with a normal level (relative risk [RR] 4.4; 95% confidence interval [CI]: 2.2 to 8.5; P ). In a multivariate logistic regression model, an increased C-reactive protein level was an independent predictor of death or nonfatal myocardial infarction (RR 3.6; 95% CI: 1.8 to 7.2; P ). The incidence of repeat revascularization was similar in patients with or without an increased C-reactive protein level (23% [168/716] vs. 22% [163/ 742], P 0.54). Statin therapy at the time of the procedure was associated with a lower mean ( SD) C-reactive protein level ( mg/l vs mg/l, P 0.02), but was not associated with the risk of death, nonfatal myocardial infarction, and repeat revascularization during follow-up. CONCLUSION: An increased C-reactive protein level is an independent prognostic indicator for the occurrence of death or nonfatal myocardial infarction following coronary angioplasty, but is not associated with the need for repeat revascularization. Am J Med. 2003;115: by Excerpta Medica Inc. C-reactive protein is an acute phase reactant synthesized by hepatocytes in response to proinflammatory cytokines, predominantly interleukin 6 (1,2). An elevated serum level of C-reactive protein, signifying activation of systemic inflammation, is associated with an adverse prognosis in patients with stable (3 6) or unstable angina (7 12) and following acute myocardial infarction (13,14). Levels of C-reactive protein may be a marker of the extent of atherosclerosis (15), or they may be associated with vulnerable plaques (16,17). In addition, an elevated C-reactive protein level may lead to cardiac events through its ability to bind complement (18,19). C-reactive protein also induces the expression of adhesion molecules on endothelial cells in serum (20) and is associated with endothelial dysfunction (21). From the Departments of Cardiology (RJDW, KTK, GH, MB, CES, KJM, JGPT, JJP) and Clinical Chemistry (JPVS, GTS, JF), Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. Requests for reprints should be addressed to Robbert J. de Winter, MD, PhD, Department of Cardiology, B2-137, Academic Medical Center, Meibergdreef 9, P.O. Box 22660, 1100 DD Amsterdam, The Netherlands, or r.j.dewinter@amc.uva.nl. Manuscript submitted June 18, 2002, and accepted in revised form February 28, Recently, it was shown that an elevated C-reactive protein level was associated with early complications following coronary angioplasty (22). Several studies have suggested that an elevated level is associated with restenosis and the need for repeat revascularization (23 27), but another study failed to confirm this association (28). The aim of our study was to assess the long-term association of C-reactive protein levels with the risk of death, nonfatal myocardial infarction, and repeat revascularization after coronary angioplasty. METHODS Patients Consecutive patients undergoing percutaneous transluminal coronary angioplasty at the catheterization laboratory at our institution were eligible. Patients undergoing elective angioplasty for stable angina (including Braunwald class I) and patients presenting with non ST-elevation acute coronary syndrome (Braunwald class II/III) were included, but patients undergoing primary angioplasty for ST-elevation myocardial infarction were excluded. All patients routinely received 5000 IU of unfractionated heparin. Before the procedure, patients were treated with aspirin (100 to 300 mg). After the procedure, 2003 by Excerpta Medica Inc /03/$ see front matter 85 All rights reserved. doi: /s (03)
2 Table 1. Baseline Clinical, Angiographic, and Procedural Characteristics Characteristic (n 716) (n 742) P Value Number (%), Mean SD, or Median (Range) Age (years) Male sex 488 (68) 568 (77) Body weight (kg) Hypertension 303 (42) 242 (33) Diabetes mellitus 120 (17) 88 (12) 0.01 Statin therapy at time of procedure 264 (37) 315 (43) 0.03 Cigarette smoking 286 (40) 252 (34) Braunwald class I vs. II/III 502 (70) 637 (86) Restenotic lesion 66 (9) 101 (14) 0.01 Stents 300 (42) 336 (45) 0.21 Percent diameter stenosis preangioplasty Lesion length (mm) Percent diameter stenosis postangioplasty C-reactive protein (mg/l) 11.9 ( ) 1.40 ( ) patients received aspirin 100 mg/d indefinitely and ticlopidine 250 mg twice daily or clopidogrel 75 mg/d for 4 weeks after stent placement. Stents were used electively in patients with chronic total occlusions, restenotic lesions, ostial lesions, or severe saphenous vein graft disease. Provisional stenting was performed as bailout or for unsatisfactory balloon result. Serial sampling of serum creatine kinase and creatine kinase MB levels was performed at the discretion of the operator. The institutional committee on human research approved the protocol. Blood was collected in heparin-coated tubes through the arterial sheath at the start of the procedure. C-reactive protein was measured with a nephelometric assay (Dade Behring Diagnostics, Marburg, Germany). For the present analysis, we defined a cutoff of 3.0 mg/l (the 90th percentile of the normal distribution) as abnormal (10,29,30). Clinical Follow-up Follow-up was obtained by sending a questionnaire to the patients 12 to 14 months after the procedure. If there was no reply or if an event was reported, review of medical records and telephone contact with the patients, their relatives, referring cardiologists, and general practitioners were used to complete follow-up information. Patients with residual or recurrent anginal symptoms requiring repeat revascularization procedures were all referred to our institution, and data about these procedures were collected. Use of medical treatment including statin therapy was recorded at the time of the procedure. Most patients were referred from other centers, and although statin treatment was advised for all patients, its prescription was at the discretion of the referring cardiologists. The primary endpoint was defined as death from all causes or nonfatal myocardial infarction. The definition of myocardial infarction included elevation of cardiac markers or the development of new Q waves on the electrocardiogram; we also included periprocedural myocardial infarctions with a creatine kinase MB peak greater than two times the upper limit of normal. Statistical Analysis Continuous variables with normal distributions were expressed as means ( SD) and compared with the unpaired Student t test. Categorical baseline variables were compared with the Fisher exact test or the chi-squared statistic, as appropriate. Multivariate logistic regression analysis was performed to establish the independent predictive value of an elevated C-reactive protein level; other variables (Table 1) were forced into the model. Kaplan- Meier survival analysis and life tables were constructed; the cumulative probabilities of death, nonfatal myocardial infarction, or repeat revascularization were compared with the log-rank test. We also investigated whether there was a relation between the level of C-reactive protein and the incidence of death, nonfatal myocardial infarction, and repeat revascularization by quartiles of C-reactive protein, using the first quartile ( 1.3 mg/l) as the comparison group. Statistical analyses were performed using the Statistical Package for Social Sciences software (SPSS 10.1 for Windows; SPSS Inc., Chicago, Illinois). P values 0.05 were considered statistically significant. 86 August 1, 2003 THE AMERICAN JOURNAL OF MEDICINE Volume 115
3 Table 2. Outcomes by Preprocedural Level Outcome (n 716) (n 742) Odds Ratio (95% Confidence Interval)* P Value Number (%) Clinical events Death 21 (2.9) 5 (0.7) 4.5 ( ) Myocardial infarction 23 (3.2) 6 (0.8) 4.1 (1.7 10) Revascularization Coronary angioplasty 149 (21) 142 (19) 1.11 ( ) 0.46 Cardiac surgery 19 (2.7) 21 (2.8) 0.94 ( ) 0.96 Composite endpoint Death/myocardial infarction 44 (6.1) 11 (1.5) 4.4 ( ) Repeat revascularization 168 (23.5) 163 (22.0) 1.09 ( ) 0.54 * Comparing patients with abnormal vs. normal C-reactive protein levels. RESULTS Patients with an abnormal C-reactive protein level ( 3 mg/l) were significantly older, more often women, more often smokers, more likely to have hypertension or diabetes, and more often in Braunwald class II or III than were those with normal levels (Table 1). Patients with abnormal levels were also less often taking statins at the time of the procedure but were more often taking statins at follow-up (37% [264/716] vs. 43% [315/742], P 0.03). Statin therapy was associated with a lower mean preprocedural C-reactive protein level ( mg/l vs mg/l, P 0.02). The proportion of patients with restenotic lesions was lower in those with elevated C-reactive protein levels. According to the modified American Heart Association classification, 2% (n 28) were type A, 26% (n 381) were type B1, 46% (n 670) were type B2, and 26% (n 379) were type C. Clinical Follow-up Follow-up was completed for all patients (Table 2). All 26 deaths were due to cardiac causes. Mortality was signifi- Figure 1. Cumulative probability of death or nonfatal myocardial infarction (MI) following percutaneous coronary angioplasty, by C-reactive protein level (P ). August 1, 2003 THE AMERICAN JOURNAL OF MEDICINE Volume
4 Figure 2. Cumulative probability of repeat revascularization (percutaneous transluminal angioplasty [PTCA] or coronary artery bypass graft [CABG] surgery) following percutaneous coronary angioplasty, by C-reactive protein level (P 0.24). cantly greater in patients with an increased C-reactive protein level, as was the incidence of nonfatal myocardial infarction (Table 2). Thus, an abnormal C-reactive protein level was strongly associated with the risk of the combined endpoint of death or nonfatal myocardial infarction. In contrast, an abnormal C-reactive protein level was not associated with repeat revascularization (23% [168/716] vs. 22% [163/742], P 0.54). There was a significant difference in the cumulative probability of death or nonfatal myocardial infarction in patients with an abnormal C-reactive protein level as compared with those who had a normal level (Figure 1; P ). There was also a slightly lower cumulative probability of repeat revascularization in patients with an abnormal level that was not statistically significant (Figure 2; P 0.24). Multivariate Analysis In a multivariate logistic regression analysis, an increased C-reactive protein level was associated with almost a Table 3. Multivariate Associations with Death or Nonfatal Myocardial Infarction, or Repeat Revascularization Characteristic Death or Myocardial Infarction Odds Ratio (95% Confidence Interval) P Value Repeat Revascularization Odds Ratio (95% Confidence Interval) P Value Age 65 years 2.62 ( ) ( ) 0.93 Male sex 0.99 ( ) ( ) 0.57 Hypertension 1.50 ( ) ( ) 0.93 Diabetes mellitus 1.74 ( ) ( ) 0.07 Statin therapy at baseline 0.75 ( ) ( ) 0.15 Cigarette smoking 1.43 ( ) ( ) 0.22 Braunwald class I (vs. class II or III) 0.64 ( ) ( ) 0.43 Restenotic lesion 0.45 ( ) ( ) 0.84 Use of stents 1.55 ( ) ( ) 0.97 Percent diameter stenosis preangioplasty ( ) ( ) 0.16 Lesion length (mm) 0.98 ( ) ( ) 0.02 Percent diameter stenosis postangioplasty ( ) ( ) C-reactive protein 3.6 ( ) ( ) August 1, 2003 THE AMERICAN JOURNAL OF MEDICINE Volume 115
5 Table 4. Quartiles of and Risk of Coronary Outcomes Outcome Quartiles of (mg/l) 1.3 (n 378) (n 364) (n 355) 7.0 (n 361) Number (%) Death or nonfatal myocardial infarction 7 (2) 4 (1) 16 (5) 28 (8) Repeat revascularization 79 (21) 84 (23) 81 (23) 87 (24) fourfold increase in the risk of death or myocardial infarction (Table 3). The use of statins at the time of the procedure was not associated with death or myocardial infarction. In multivariate analyses, diabetes, lesion length, and percent diameter stenosis after angioplasty were significant independent predictors of repeat revascularization, whereas an abnormal C-reactive protein level was not. Level and Outcomes When patients were categorized by quartiles of C-reactive protein level (Table 4), there was a higher risk of death or nonfatal myocardial infarction for the third and fourth quartiles compared with the first quartile (P 0.09 for the third quartile; P for the fourth quartile). The risks of repeat revascularization were similar among quartiles of C-reactive protein level. DISCUSSION We found that C-reactive protein level was a significant independent predictor of death or nonfatal myocardial infarction following percutaneous coronary intervention. Although increased levels were associated with several patient characteristics, including age, sex, diabetes, smoking, and Braunwald class, which are known to influence C-reactive protein levels, C-reactive protein was still associated with these outcomes after multivariate adjustment. In contrast with previous reports, we failed to show an association between C-reactive protein levels and repeat revascularizations for restenosis, irrespective of stent placement. Previous studies of the association between C-reactive protein levels and restenosis have been conflicting. Buffon et al (23) described an association between C-reactive protein levels and late clinical restenosis during a 1-year follow-up in 52 patients with stable angina and 59 patients with unstable who had single-vessel disease. Another study involving 447 patients reported that a C-reactive protein level 10 mg/l was an independent predictor of repeated coronary revascularization (26). A recent report indicated that an elevated C-reactive protein level carried a more than twofold increased risk of death, myocardial infarction, or revascularization during 6 months of follow-up; the increase in risk was attenuated by statin therapy (27). However, in an atherectomy and restenosis study, Zhou et al could not demonstrate a relation between C-reactive protein levels and the occurrence of angiographic restenosis (28). Finally, a large study by Chew et al (22) showed a strong association between an elevated C-reactive protein level and 30-day complications. However, late restenosis was not reported. Several studies have shown that statins lower C-reactive protein levels independent of their effects on lowdensity lipoprotein cholesterol levels (31,32). This includes both short- and long-term effects (33 35). Indeed, a recent study found that statin therapy reduced the risk of death, myocardial infarction, or repeat revascularization following angioplasty in patients with cholesterol levels between 3.5 and 7.0 mmol/l, although the benefits (as compared with placebo) were not apparent until 1.5 years of follow-up (36). Our study has several limitations. First, it was conducted at a single center. However, the patients are representative of those undergoing percutaneous coronary angioplasty. Second, although follow-up was thorough, there were no systematic follow-up visits and no repeat electrocardiograms; thus, silent myocardial infarctions may have been missed. Finally, we could not demonstrate an association between statin treatment at the time of the procedure and prognosis during the 12 to 14 months of follow-up. Perhaps a larger study or a longer follow-up is necessary, or it may take higher doses of statins for the beneficial effects to become apparent (patients in our study were usually taking simvastatin 10 to 20 mg/d, pravastatin 20 mg/d, or atorvastatin 10 mg/d). In conclusion, our study shows that C-reactive protein levels are increased in nearly 50% of patients undergoing percutaneous coronary angioplasty. An increased level was an independent prognostic indicator for death or nonfatal myocardial infarction during follow-up, but not for repeat revascularization. ACKNOWLEDGMENT We are very grateful to the nursing staff of the catheterization laboratory of the Academic Medical Center of the University of Amsterdam and to all the cardiologists and general practitioners who kindly assisted in the follow-up. August 1, 2003 THE AMERICAN JOURNAL OF MEDICINE Volume
6 REFERENCES 1. Brakenhoff JPJ, de Groot ER, Evers RF, Pannekoek H, Aarden LA. Molecular cloning and expression of hybridoma growth factor in Escherichia coli. J Immunol. 1987;139: Kishimoto T, Akira S, Narazaki M, Taga T. Interleukin-6 family of cytokines and gp130. Blood. 1995;86: Haverkate F, Thompson SG, Pyke SDM, Gallimore JR, Pepys MB. Production of C-reactive protein and risk of coronary events in stable and unstable angina. Lancet. 1997;349: Kuller LH, Tracy RP, Shaten J, Meilahn EN. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial. Am J Epidemiol. 1996;144: Tracy RP, Lemaitre RN, Psaty BM, et al. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the Cardiovascular Health Study and the Rural Health Promotion Project. Arterioscler Thromb Vasc Biol. 1997;17: Anderson JL, Muhlestein JB, Horne BD, et al. Plasma homocysteine predicts mortality independently of traditional risk factors and C- reactive protein in patients with angiographically defined coronary artery disease. Circulation. 2000;102: Liuzzo G, Biasucci LM, Gallimore JR, et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med. 1994;331: De Winter RJ, Bholasingh R, Lijmer JG, et al. Independent prognostic value of C-reactive protein and troponin I in patients with unstable angina or non-q-wave myocardial infarction. Cardiovasc Res. 1999;42: Rebuzzi AG, Quaranta G, Liuzzo G, et al. Incremental prognostic value of serum levels of troponin T and C-reactive protein on admission in patients with unstable angina pectoris. Am J Cardiol. 1998;82: Biasucci LM, Liuzzo G, Grillo RL, et al. Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability. Circulation. 1999;99: Ferreiros ER, Boissonnet CP, Pizarro R, et al. Independent prognostic value of elevated C-reactive protein in unstable angina. Circulation. 1999;100: Lindahl B, Toss H, Siegbahn A, Venge P, Wallentin L, FRISC Study Group. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. Fragmin during Instability in Coronary Artery Disease. N Engl J Med. 2000;343: Pietila K, Harmoinen A, Teppo AM. Acute phase reaction, infarct size and in-hospital morbidity in myocardial infarction patients treated with streptokinase or recombinant tissue type plasminogen activator. Ann Med. 1991;23: Pietila K, Harmoinen A, Hermens W, et al. Serum C-reactive protein and infarct size in myocardial infarct patients with a closed versus an open infarct-related coronary artery after thrombolytic therapy. Eur Heart J. 1993;14: Zhu J, Quyyumi AA, Norman JE, et al. Effects of total pathogen burden on coronary artery disease risk and C-reactive protein levels. Am J Cardiol. 2000;85: Zhu J, Quyyumi AA, Norman JE, Csako G, Epstein SE. Cytomegalovirus in the pathogenesis of atherosclerosis: the role of inflammation as reflected by elevated C-reactive protein levels. J Am Coll Cardiol. 1999;34: Roivainen M, Viik-Kajander M, Palosuo T, et al. Infections, inflammation, and the risk of coronary heart disease. Circulation. 2000; 101: Hack CE, Wolbink GJ, Schalkwijk C, et al. A role for secretory phospholipase A2 and C-reactive protein in the removal of injured cells. Immunol Today. 1997;18: Lagrand WK, Visser CA, Hermens WT, et al. C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon? Circulation. 1999;100: Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation. 2000; 102: Fichtlscherer S, Rosenberger G, Walter DH, et al. Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease. Circulation. 2000;102: Chew DP, Bhatt DL, Robbins MA, et al. Incremental prognostic value of elevated baseline C-reactive protein among established markers of risk in percutaneous coronary intervention. Circulation. 2001;104: Buffon A, Liuzzo G, Biasucci LM, et al. Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty. J Am Coll Cardiol. 1999;34: Gaspardone A, Crea F, Versaci F, et al. Predictive value of C-reactive protein after successful coronary-artery stenting in patients with stable angina. Am J Cardiol. 1998;82: Versaci F, Gaspardone A, Tomai F, et al. Predictive value of C-reactive protein in patients with unstable angina pectoris undergoing coronary artery stent implantation. Am J Cardiol. 2000;85: Heeschen C, Hamm CW, Bruemmer J, Simoons ML. Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysis. CAPTURE Investigators. Chimeric c7e3 AntiPlatelet Therapy in Unstable angina REfractory to standard treatment trial. J Am Coll Cardiol. 2000;35: Walter DH, Fichtlscherer S, Britten MB, et al. Statin therapy, inflammation and recurrent coronary events in patients following coronary stent implantation. J Am Coll Cardiol. 2001;38: Zhou YF, Csako G, Grayston JT, et al. Lack of association of restenosis following coronary angioplasty with elevated C-reactive protein levels or seropositivity to Chlamydia pneumoniae. Am J Cardiol. 1999;84: Liuzzo G, Biasucci LM, Rebuzzi AG, et al. Plasma protein acutephase response in unstable angina is not induced by ischemic injury. Circulation. 1996;94: Liuzzo G, Biasucci L, Gallimore JR, et al. Enhanced inflammatory response in patients with pre-infarction unstable angina. J Am Coll Cardiol. 1999;34: Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E, The Cholesterol and Recurrent Events (CARE) Investigators. Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation. 1999;100: Ridker PM, Rifai N, Pfeffer MA, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation. 1998;98: Albert MA, Staggers J, Chew P, Ridker PM. The Pravastatin Inflammation CRP Evaluation (PRINCE): rationale and design. Am Heart J. 2001;141: Albert MA, Danielson E, Rifai N, Ridker PM. Effect of statin therapy on C-reactive protein levels: the Pravastatin Inflammation/CRP Evaluation (PRINCE): a randomized trial and cohort study. JAMA. 2001;286: Jialal I, Stein D, Balis D, et al. Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation. 2001;103: Serruys PW, de Feyter P, Macaya C, et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;287: August 1, 2003 THE AMERICAN JOURNAL OF MEDICINE Volume 115
Prognostic Significance of High Sensitivity C-Reactive Protein before and after Percutaneous Coronary Intervention in Patients with Angina Pectoris
Med. J. Cairo Univ., Vol. 80, No. 2, June: 267-272, 2012 www.medicaljournalofcairouniversity.com Prognostic Significance of High Sensitivity C-Reactive Protein before and after Percutaneous Coronary Intervention
More informationPrognostic Value of C-Reactive Protein and Troponin T Level in Patients With Unstable Angina Pectoris C T KASANUKI, MD, FJCC
C T Prognostic Value of C-Reactive Protein and Troponin T Level in Patients With Unstable Angina Pectoris Hiroyuki Yukio Hiroshi TANAKA, MD TSURUMI, MD KASANUKI, MD, FJCC Abstract Objectives. The prognosis
More informationInflammation plays a pivotal role in the pathogenesis of
Relation of Inflammation and Benefit of Statins After Percutaneous Coronary Interventions Albert W. Chan, MD, MSc; Deepak L. Bhatt, MD; Derek P. Chew, MBBS, MPH; Joel Reginelli, MD; Jakob P. Schneider,
More informationIncremental Prognostic Value of Elevated Baseline C-Reactive Protein Among Established Markers of Risk in Percutaneous Coronary Intervention
Incremental Prognostic Value of Elevated Baseline C-Reactive Protein Among Established Markers of Risk in Percutaneous Coronary Intervention Derek P. Chew, MBBS; Deepak L. Bhatt, MD; Mark A. Robbins, MD;
More informationIschemic heart disease is the leading cause of
The impact of C-Reactive Protein: A Look at the Most Recent Studies and Trials By Davinder S. Jassal, MD, FRCPC; and Blair O Neill, MD, FRCPC, FACC Ischemic heart disease is the world s leading killer,
More informationC-Reactive Protein and Angiographic Coronary Artery Disease: Independent and Additive Predictors of Risk in Subjects With Angina
Journal of the American College of Cardiology Vol. 39, No. 4, 2002 2002 by the American College of Cardiology ISSN 0735-1097/02/$22.00 Published by Elsevier Science Inc. PII S0735-1097(01)01804-6 C-Reactive
More informationDoes high-sensitivity C-reactive protein add prognostic value to the TIMI-Risk Score in individuals with non-st elevation acute coronary syndromes?
Clinica Chimica Acta 375 (2007) 124 128 www.elsevier.com/locate/clinchim Does high-sensitivity C-reactive protein add prognostic value to the TIMI-Risk Score in individuals with non-st elevation acute
More informationThe New England Journal of Medicine C-REACTIVE PROTEIN AND OTHER MARKERS OF INFLAMMATION IN THE PREDICTION OF CARDIOVASCULAR DISEASE IN WOMEN
C-REACTIVE PROTEIN AND OTHER MARKERS OF INFLAMMATION IN THE PREDICTION OF CARDIOVASCULAR DISEASE IN WOMEN PAUL M. RIDKER, M.D., CHARLES H. HENNEKENS, M.D., JULIE E. BURING, SC.D., AND NADER RIFAI, PH.D.
More informationThe impact of hs C-reactive protein and other inflammatory biomarkers on long-term cardiovascular mortality in patients with acute coronary syndromes
Atherosclerosis 194 (2007) 397 402 The impact of hs C-reactive protein and other inflammatory biomarkers on long-term cardiovascular mortality in patients with acute coronary syndromes Michael N. Zairis,
More informationInfluence of Planned Six-Month Follow-Up Angiography on Late Outcome After Percutaneous Coronary Intervention A Randomized Study
Journal of the American College of Cardiology Vol. 38, No. 4, 2001 2001 by the American College of Cardiology ISSN 0735-1097/01/$20.00 Published by Elsevier Science Inc. PII S0735-1097(01)01476-0 Influence
More informationC-Reactive Protein Levels and Outcomes after Statin Therapy
The new england journal of medicine original article C-Reactive Protein Levels and Outcomes after Statin Therapy Paul M Ridker, M.D., Christopher P. Cannon, M.D., David Morrow, M.D., Nader Rifai, Ph.D.,
More informationFatality of Future Coronary Events Is Related to Inflammation-Sensitive Plasma Proteins
Fatality of Future Coronary Events Is Related to Inflammation-Sensitive Plasma Proteins A Population-Based Prospective Cohort Study Gunnar Engström, MD; Bo Hedblad, MD; Lars Stavenow, MD; Patrik Tydén,
More informationPre-procedural plasma levels of C-reactive protein and interleukin-6 do not predict late coronary angiographic restenosis after elective stenting
European Heart Journal () 5, 19 135 Clinical research Pre-procedural plasma levels of C-reactive protein and interleukin- do not predict late coronary angiographic restenosis after elective stenting Amit
More informationIn an attempt to improve global cardiovascular risk
MINI-REVIEW: EXPERT OPINIONS Clinical Application of C-Reactive Protein for Cardiovascular Disease Detection and Prevention Paul M Ridker, MD In an attempt to improve global cardiovascular risk prediction,
More informationIn-Ho Chae. Seoul National University College of Medicine
The Earlier, The Better: Quantum Progress in ACS In-Ho Chae Seoul National University College of Medicine Quantum Leap in Statin Landmark Trials in ACS patients Randomized Controlled Studies of Lipid-Lowering
More informationPercutaneous Coronary Interventions Without On-site Cardiac Surgery
Percutaneous Coronary Interventions Without On-site Cardiac Surgery Hassan Al Zammar, MD,FESC Consultant & Interventional Cardiologist Head of Cardiology Department European Gaza Hospital Palestine European
More informationJournal of the American College of Cardiology Vol. 36, No. 1, by the American College of Cardiology ISSN /00/$20.
Journal of the American College of Cardiology Vol. 36, No. 1, 2000 2000 by the American College of Cardiology ISSN 0735-1097/00/$20.00 Published by Elsevier Science Inc. PII S0735-1097(00)00680-X Lack
More informationPrevention of Coronary Stent Thrombosis and Restenosis
Prevention of Coronary Stent Thrombosis and Restenosis Seong-Wook Park, MD, PhD, FACC Division of Cardiology, Asan Medical Center University of Ulsan College of Medicine, Seoul, Korea 9/12/03 Coronary
More informationARMYDA-RECAPTURE (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) trial
ARMYDA-RECAPTURE ( for Reduction of MYocardial Damage during Angioplasty) trial Prospective, multicenter, randomized, double blind trial investigating efficacy of atorvastatin reload in patients on chronic
More informationClinical Investigation and Reports. Long-Term Effects of Pravastatin on Plasma Concentration of C-reactive Protein
Clinical Investigation and Reports Long-Term Effects of Pravastatin on Plasma Concentration of C-reactive Protein Paul M. Ridker, MD; Nader Rifai, PhD; Marc A. Pfeffer, MD; Frank Sacks, MD; Eugene Braunwald,
More informationRisk stratification in unstable angina and non-q wave myocardial infarction using soluble cell adhesion molecules
Heart 21;85:623 627 623 Royal City of Dublin Hospital Research and Education Institute, Department of Cardiology, St James s Hospital, Dublin 8, Ireland N T Mulvihill J B Foley R T Murphy R Curtin P A
More informationThe Framingham Coronary Heart Disease Risk Score
Plasma Concentration of C-Reactive Protein and the Calculated Framingham Coronary Heart Disease Risk Score Michelle A. Albert, MD, MPH; Robert J. Glynn, PhD; Paul M Ridker, MD, MPH Background Although
More informationTRIAS HR Pilot Study
Late Breaking Clinical Trials TCT, October 22 nd 27, Washington, USA TRIAS HR Pilot Study RCT comparing Genous EPC capturing stent with Taxus Paclitaxel eluting stent Robbert J de Winter MD PhD FESC Academic
More informationAbstract Background: Methods: Results: Conclusions:
Two-Year Clinical and Angiographic Outcomes of Overlapping Sirolimusversus Paclitaxel- Eluting Stents in the Treatment of Diffuse Long Coronary Lesions Kang-Yin Chen 1,2, Seung-Woon Rha 1, Yong-Jian Li
More informationRuling out acute myocardial infarction early with two serial creatine kinase-mb mass determinations
European Heart Journal (1999) 20, 967 972 Article No. euhj.1998.1449, available online at http://www.idealibrary.com on Ruling out acute myocardial infarction early with two serial creatine kinase-mb mass
More informationCardiac Troponin I Levels and Clinical Outcomes in Patients With Acute Coronary Syndromes The Potential Role of Early Percutaneous Revascularization
Journal of the American College of Cardiology Vol. 34, No. 6, 1999 1999 by the American College of Cardiology ISSN 0735-1097/99/$20.00 Published by Elsevier Science Inc. PII S0735-1097(99)00434-9 Cardiac
More informationRole of Clopidogrel in Acute Coronary Syndromes. Hossam Kandil,, MD. Professor of Cardiology Cairo University
Role of Clopidogrel in Acute Coronary Syndromes Hossam Kandil,, MD Professor of Cardiology Cairo University ACS Treatment Strategies Reperfusion/Revascularization Therapy Thrombolysis PCI (with/ without
More informationClinical Study Age Differences in Long Term Outcomes of Coronary Patients Treated with Drug Eluting Stents at a Tertiary Medical Center
Aging Research Volume 2013, Article ID 471026, 4 pages http://dx.doi.org/10.1155/2013/471026 Clinical Study Age Differences in Long Term Outcomes of Coronary Patients Treated with Drug Eluting Stents at
More informationA Randomized Comparison of Clopidogrel and Aspirin Versus Ticlopidine and Aspirin After the Placement of Coronary Artery Stents
Journal of the American College of Cardiology Vol. 41, No. 6, 2003 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00 Published by Elsevier Science Inc. doi:10.1016/s0735-1097(02)02974-1
More informationthe prognostic significance of C-reactive protein as an independent predictor for coronary events in Patients presenting with chest pain
ISPUB.COM The Internet Journal of Cardiology Volume 8 Number 1 the prognostic significance of C-reactive protein as an independent predictor for coronary events in Patients presenting with chest pain A
More informationAmple experimental evidence indicates that cytomegalovirus
Cytomegalovirus Infection With Interleukin-6 Response Predicts Cardiac Mortality in Patients With Coronary Artery Disease Stefan Blankenberg, MD; Hans J. Rupprecht, MD; Christoph Bickel, MD; Christine
More informationConnecting the Role of C-Reactive Protein and Statins in Cardiovascular Disease
Clin. Cardiol. Vol. 26 (Suppl. III), III-39 III-44 (2003) Connecting the Role of C-Reactive Protein and Statins in Cardiovascular Disease PAUL M. RIDKER, M.D., M.P.H., FACC Center for Cardiovascular Disease
More informationMARKERS OF MYOCARDIAL DAMAGE AND INFLAMMATION IN RELATION TO LONG-TERM MORTALITY
MARKERS OF MYOCARDIAL DAMAGE AND INFLAMMATION IN RELATION TO LONG-TERM MORTALITY IN UNSTABLE CORONARY ARTERY DISEASE BERTIL LINDAHL, M.D., PH.D., HENRIK TOSS, M.D., AGNETA SIEGBAHN, M.D., PH.D., PER VENGE,
More informationJournal of the American College of Cardiology Vol. 35, No. 5, by the American College of Cardiology ISSN /00/$20.
Journal of the American College of Cardiology Vol. 35, No. 5, 2000 2000 by the American College of Cardiology ISSN 0735-1097/00/$20.00 Published by Elsevier Science Inc. PII S0735-1097(00)00546-5 CLINICAL
More informationATHEROSCLEROSIS IS CHARACterized
ORIGINAL CONTRIBUTION Relationship Between Interleukin 6 and Mortality in Patients With Unstable Coronary Artery Disease Effects of an Early Invasive or Noninvasive Eva Lindmark, MMed Erik Diderholm, MD
More informationPathology of percutaneous interventions (PCI) in coronary arteries. Allard van der Wal, MD.PhD; Pathologie AMC, Amsterdam, NL
Pathology of percutaneous interventions (PCI) in coronary arteries Allard van der Wal, MD.PhD; Pathologie AMC, Amsterdam, NL Percutaneous Coronary Intervention (PCI) Definition: transcatheter opening of
More informationClinical Investigations
Clinical Investigations Clinical Outcomes for Single Stent and Multiple Stents in Contemporary Practice Qiao Shu Bin, MD; Liu Sheng Wen, MD; Xu Bo, BS; Chen Jue, MD; Liu Hai Bo, MD; Yang Yue Jin, MD; Chen
More informationBalloon Angioplasty and Stent Implantation Induce a Vascular Inflammatory Reaction
J ENDOVASC THER 59 CLINICAL INVESTIGATION Balloon and Stent Implantation Induce a Vascular Inflammatory Reaction Martin Schillinger, MD; Markus Exner, MD*; Wolfgang Mlekusch, MD; Markus Haumer, MD; Ramazanali
More informationSupplementary Online Content
Supplementary Online Content Leibowitz M, Karpati T, Cohen-Stavi CJ, et al. Association between achieved low-density lipoprotein levels and major adverse cardiac events in patients with stable ischemic
More informationComparison of Effects of High (80 mg) Versus Low (20 mg) Dose of Simvastatin
Comparison of Effects of High (80 mg) Versus Low (20 mg) Dose of Simvastatin on C-Reactive Protein and Lipoproteins in Patients With Angiographic Evidence of Coronary Arterial Narrowing Kent G. Meredith,
More informationImpact of coronary atherosclerotic burden on clinical presentation and prognosis of patients with coronary artery disease
Impact of coronary atherosclerotic burden on clinical presentation and prognosis of patients with coronary artery disease Gjin Ndrepepa, Tomohisa Tada, Massimiliano Fusaro, Lamin King, Martin Hadamitzky,
More informationJournal of the American College of Cardiology Vol. 47, No. 7, by the American College of Cardiology Foundation ISSN /06/$32.
Journal of the American College of Cardiology Vol. 47, No. 7, 2006 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.05.102
More informationCardiovascular risk and therapeutic benefit of coronary interventions for patients with unstable angina according to the troponin T status
European Heart Journal (2000) 21, 1159 1166 doi:10.1053/euhj.1999.1986, available online at http://www.idealibrary.com on Cardiovascular risk and therapeutic benefit of coronary interventions for patients
More informationTreatment strategies and risk stratification in acute coronary syndromes Damman, P.
UvA-DARE (Digital Academic Repository) Treatment strategies and risk stratification in acute coronary syndromes Damman, P. Link to publication Citation for published version (APA): Damman, P. (2013). Treatment
More informationA Comparative Evaluation of C-Reactive Protein as a Short-Term Prognostic Marker in Severe Unstable Angina A Preliminary Study
Original Article A Comparative Evaluation of C-Reactive Protein as a Short-Term Prognostic Marker in Severe Unstable Angina A Preliminary Study S Bhagat*, M Gaiha*, VK Sharma**, S Anuradha* Abstract Objective
More informationI t is becoming increasingly clear that inflammation plays a
25 CARDIOVASCULAR MEDICINE Raised concentrations of macrophage colony stimulating factor in severe unstable angina beyond the acute phase are strongly predictive of long term outcome L S Rallidis, M G
More informationJournal of the American College of Cardiology Vol. 46, No. 8, by the American College of Cardiology Foundation ISSN /05/$30.
Journal of the American College of Cardiology Vol. 46, No. 8, 2005 2005 by the American College of Cardiology Foundation ISSN 0735-1097/05/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.06.070
More informationPCI for Left Anterior Descending Artery Ostial Stenosis
PCI for Left Anterior Descending Artery Ostial Stenosis Why do you hesitate PCI for LAD ostial stenosis? LAD Ostial Lesion Limitations of PCI High elastic recoil Involvement of the distal left main coronary
More informationORIGINAL INVESTIGATION
ORIGINAL INVESTIGATION Age and Duration of Follow-up as Modulators of the Risk for Ischemic Heart Disease Associated With High Plasma C-Reactive Protein Levels in Men Matteo Pirro, MD; Jean Bergeron, MD;
More informationCase Study 50 YEAR OLD MALE WITH UNSTABLE ANGINA
Case Study 50 YEAR OLD MALE WITH UNSTABLE ANGINA Case History A 50-year-old man with type 1 diabetes mellitus and hypertension presents after experiencing 1 hour of midsternal chest pain that began after
More informationMultiple Inflammatory Prognostic Factors in Acute Coronary Syndromes: A Prospective Inception Cohort Study
ORIGINAL REPORT Multiple Inflammatory Prognostic Factors in Acute Coronary Syndromes: A Prospective Inception Cohort Study Zinat Nadia Hatmi *1, Ali Kazemi Saeid 2, Mohammad Ali Broumand 3, Shabnam Najar
More informationDespite intensive basic and clinical investigation, coronary
Current Perspective Need to Test the Arterial Inflammation Hypothesis Deepak L. Bhatt, MD; Eric J. Topol, MD Despite intensive basic and clinical investigation, coronary artery disease remains the principal
More informationPlasma Concentration of C-Reactive Protein and Risk of Ischemic Stroke and Transient Ischemic Attack. The Framingham Study
Plasma Concentration of C-Reactive Protein and Risk of Ischemic Stroke and Transient Ischemic Attack The Framingham Study Natalia S. Rost, MA; Philip A. Wolf, MD; Carlos S. Kase, MD; Margaret Kelly-Hayes,
More informationCardiovascular Health Nova Scotia Update to Antiplatelet Sections of the Nova Scotia Guidelines for Acute Coronary Syndromes, 2008.
Cardiovascular Health Nova Scotia Update to Antiplatelet Sections of the Nova Scotia Guidelines for Acute Coronary Syndromes, 2008. ST Elevation Myocardial Infarction (STEMI)-Acute Coronary Syndrome Guidelines:
More informationStatin pretreatment and presentation patterns in patients with acute coronary syndromes
Brief Report Page 1 of 5 Statin pretreatment and presentation patterns in patients with acute coronary syndromes Marcelo Trivi, Ruth Henquin, Juan Costabel, Diego Conde Cardiovascular Institute of Buenos
More informationPatients with acute coronary syndromes (ACS) are characterized
Myeloperoxidase Serum Levels Predict Risk in Patients With Acute Coronary Syndromes Stephan Baldus, MD*; Christopher Heeschen, MD*; Thomas Meinertz, MD; Andreas M. Zeiher, MD; Jason P. Eiserich, PhD; Thomas
More informationThe MAIN-COMPARE Study
Long-Term Outcomes of Coronary Stent Implantation versus Bypass Surgery for the Treatment of Unprotected Left Main Coronary Artery Disease Revascularization for Unprotected Left MAIN Coronary Artery Stenosis:
More informationUnprotected Left Main Stenting: Patient Selection and Recent Experience. Alaide Chieffo. S. Raffaele Hospital, Milan, Italy
Unprotected Left Main Stenting: Patient Selection and Recent Experience Alaide Chieffo S. Raffaele Hospital, Milan, Italy Class IIa (Level B) AHA/ACC 2005 Guidelines Left Main CAD The use of PCI for pts
More informationBMR Medicine. Research Article
www.bmrjournals.com Open Access Scientific Publisher Research Article RELATIONSHIP BETWEEN WHITE BLOOD CELL (WBC) COUNT AND C-REACTIVE PROTEIN (CRP) WITH ANGIOGRAPHIC SEVERITY OF CORONARY ARTERY DISEASE
More informationCangrelor: Is it the new CHAMPION for PCI? Robert Barcelona, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Intensive Care Unit November 13, 2015
Cangrelor: Is it the new CHAMPION for PCI? Robert Barcelona, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Intensive Care Unit November 13, 2015 Objectives Review the pharmacology and pharmacokinetic
More informationBy Graham C. Wong, MD; and Christian Constance, MD. therapy in reducing long-term cardiovascular
Lipid-Lowering Therapy For Acute Coronary Syndromes There is a large amount of evidence that supports the early use of statins in the treatment of acute coronary syndromes. The anti-inflammatory, anti-thrombotic
More informationAre Asian Patients Different? - Updates Of Biomatrix Experience In Regional Settings: BEACON II (3 Yr F up) &
Are Asian Patients Different? - Updates Of Biomatrix Experience In Regional Settings: BEACON II (3 Yr F up) & Biomatrix TM Single Center Experience (Indonesia)(Final 5 Yr F up) T. Santoso University of
More informationKorea University Guro Hospital, Seoul, Korea * Chonnam National University Hospital, Gwangju, Korea
Left Main Disease versus Non Left Main Disease in Acute Myocardial Infarction Patients in Real world Clinical Practice : Lessons from Korea Acute Myocardial Infarction Registry (KAMIR) Seung-Woon Rha*,
More informationC-reactive protein in acute coronary syndrome: association with 3-year outcomes
ISSN 0100-879X Volume 42 (12) 1119-1247 December 2009 BIOMEDICAL SCIENCES AND CLINICAL INVESTIGATION Braz J Med Biol Res, December 2009, Volume 42(12) 1236-1241 C-reactive protein in acute coronary syndrome:
More informationHigh-Sensitivity C-Reactive Protein: A Novel and Promising Marker of Coronary Heart Disease
Clinical Chemistry 47:3 403 411 (2001) Review High-Sensitivity C-Reactive Protein: A Novel and Promising Marker of Coronary Heart Disease Nader Rifai 1,2,4* and Paul M. Ridker 2,3,5 1 Department of Laboratory
More informationCoronary Artery Bypass Grafting Versus Coronary Implantation of Sirolimus-Eluting Stents in Patients with Diabetic Retinopathy
Coronary Artery Bypass Grafting Versus Coronary Implantation of Sirolimus-Eluting Stents in Patients with Diabetic Retinopathy Takayuki Ohno, MD, Shinichi Takamoto, MD, Noboru Motomura, MD, Minoru Ono,
More informationC- REACTIVE PROTEIN IN PATIENTS WITH NSTEMI ACUTE CORONARY SYNDROME
C- REACTIVE PROTEIN IN PATIENTS WITH NSTEMI ACUTE CORONARY SYNDROME Dubey RK *, Dhakal N **, Das BKL **, Pandey NK ***, Baral N **, Lamsal M ** * Department of Biochemistry, Universal College of Medical
More informationLM stenting - Cypher
LM stenting - Cypher Left main stenting with BMS Since 1995 Issues in BMS era AMC Restenosis and TLR (%) 3 27 TLR P=.282 Restenosis P=.71 28 2 1 15 12 Ostium 5 4 Shaft Bifurcation Left main stenting with
More informationStatins in the elderly: What evidence of their benefit in prevention?
Archives of Cardiovascular Disease (2010) 103, 61 65 SCIENTIFIC EDITORIAL Statins in the elderly: What evidence of their benefit in prevention? Les statines chez les personnes âgées : quelle preuve de
More informationKomplexe Koronarintervention heute: Von Syntax zu bioresorbierbaren Stents
Komplexe Koronarintervention heute: Von Syntax zu bioresorbierbaren Stents Prof. Dr. med. Julinda Mehilli Medizinische Klinik und Poliklinik I Klinikum der Universität München Campus Großhadern Key Factors
More informationQUT Digital Repository:
QUT Digital Repository: http://eprints.qut.edu.au/ This is the author s version of this journal article. Published as: Doggrell, Sheila (2010) New drugs for the treatment of coronary artery syndromes.
More informationJournal of the American College of Cardiology Vol. 38, No. 4, by the American College of Cardiology ISSN /01/$20.
Journal of the American College of Cardiology Vol. 38, No. 4, 2001 2001 by the American College of Cardiology ISSN 0735-1097/01/$20.00 Published by Elsevier Science Inc. PII S0735-1097(01)01503-0 Acute
More informationEvaluation of hs-crp levels in acute coronary syndromes
Original Research Article Evaluation of hs-crp levels in acute coronary syndromes R. S. Pushpa Kumari 1*, Priya John 2, V. A. Vipula 3 1 Professor, Department of General Medicine, MNR Medical College and
More informationSurgical vs. Percutaneous Revascularization in Patients with Diabetes and Acute Coronary Syndrome
Surgical vs. Percutaneous Revascularization in Patients with Diabetes and Acute Coronary Syndrome Chris C. Cook, MD Associate Professor of Surgery Director, CT Residency Program, WVU ACOI 10/17/18 No Disclosures
More informationThe updated guidelines from the National
BEYOND NCEP ATP III: LESSONS LEARNED AND FUTURE DIRECTIONS * Benjamin J. Ansell, MD, FACP ABSTRACT The National Cholesterol Education Program (NCEP) Third Adult Treatment Panel (ATP III) guidelines provide
More informationDifferential Expression of Cardiac Biomarkers by Gender in Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction
Differential Expression of Cardiac Biomarkers by Gender in Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction A TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy
More informationClinical Trial Synopsis TL-OPI-516, NCT#
Clinical Trial Synopsis, NCT#00225277 Title of Study: A Double-Blind, Randomized, Comparator-Controlled Study in Subjects With Type 2 Diabetes Mellitus Comparing the Effects of Pioglitazone HCl Versus
More informationRationale for Percutaneous Revascularization ESC 2011
Rationale for Percutaneous Revascularization Marie Claude Morice, Massy FR MD, FESC, FACC ESC 2011 Paris Villepinte - 27-31 August, 2011 Massy, France Potential conflicts of interest I have the following
More informationSafety and Efficacy of Coronary Stent Implantation. Acute and Six Month Outcomes of 1,126 Consecutive Patients Treated in 1996 and 1997
Original Article Safety and Efficacy of Coronary Stent Implantation. Acute and Six Month Outcomes of 1,126 Consecutive Patients Treated in 1996 and 1997 Luiz Alberto Mattos, Ibraim Pinto, Alexandre Abizaid,
More informationISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions
Julinda Mehilli, MD Deutsches Herzzentrum Technische Universität Munich Germany ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions Background Left main
More informationTHE CURRENT SITUATION AND FUTURE OF THE PERCUTANEOUS CORONARY INTERVENTION FOR ACUTE CORONARY SYNDROM IN RUSSIAN FEDERATION
: 616.127-005.8 -..,.. -...,, ( ), 2011, 581 182. 195 592 ( ) 385 590 -. 4,3 % 8,8 % ( ). 2011 62 329,, 24 931 (40 %) -. : - - ; ; 70 % ST ( ST); ST - 24. : ST,. THE CURRENT SITUATION AND FUTURE OF THE
More informationJournal of the American College of Cardiology Vol. 35, No. 4, by the American College of Cardiology ISSN /00/$20.
Journal of the American College of Cardiology Vol. 35, No. 4, 2000 2000 by the American College of Cardiology ISSN 0735-1097/00/$20.00 Published by Elsevier Science Inc. PII S0735-1097(99)00643-9 Early
More informationP ostprocedural creatine kinase and its MB isoform
1181 INTERVENTIONAL CARDIOLOGY AND SURGERY Prognostic role of cardiac troponin I after percutaneous coronary intervention in stable coronary disease T Nageh, R A Sherwood, B M Harris, M R Thomas... See
More informationThe FRISC II ECG substudy
European Heart Journal (22) 23, 41 49 doi:1.153/euhj.21.2694, available online at http://www.idealibrary.com on ST depression in ECG at entry indicates severe coronary lesions and large benefits of an
More informationInfluence of Treatment Delay on Infarct Size and Clinical Outcome in Patients With Acute Myocardial Infarction Treated With Primary Angioplasty
629 Influence of Treatment Delay on Infarct Size and Clinical Outcome in Patients With Acute Myocardial Infarction Treated With Primary Angioplasty AYLEE L. LIEM, MD, ARNOUD W.J. VAN T HOF, MD, JAN C.A.
More informationAssessing Cardiovascular Disease Risk with HS-C-reactive. California Technology Assessment Forum
TITLE: Assessing Cardiovascular Disease Risk with HS-C-reactive Protein AUTHOR: Judith Walsh, M.D., MPH Professor of Medicine Division of General Internal Medicine Department of Medicine University of
More informationDual Antiplatelet Therapy Made Practical
Dual Antiplatelet Therapy Made Practical David Parra, Pharm.D., FCCP, BCPS Clinical Pharmacy Program Manager in Cardiology/Anticoagulation VISN 8 Pharmacy Benefits Management Clinical Associate Professor
More informationCase Report Left Main Stenosis. Percutaneous Coronary Intervention (PCI) or Coronary Artery Bypass Graft Surgery (CABG)?
Cronicon OPEN ACCESS CARDIOLOGY Case Report Left Main Stenosis. Percutaneous Coronary Intervention (PCI) or Coronary Artery Bypass Graft Surgery (CABG)? Valentin Hristov* Department of Cardiology, Specialized
More informationUnprotected LM intervention
Unprotected LM intervention Guideline for COMBAT Seung-Jung Park, MD, PhD Professor of Internal Medicine, Seoul, Korea Current Recommendation for unprotected LMCA Stenosis Class IIb C in ESC guideline
More informationJournal of the American College of Cardiology Vol. 37, No. 2, by the American College of Cardiology ISSN /01/$20.
Journal of the American College of Cardiology Vol. 37, No. 2, 2001 2001 by the American College of Cardiology ISSN 0735-1097/01/$20.00 Published by Elsevier Science Inc. PII S0735-1097(00)01133-5 Coronary
More informationContemporary Percutaneous Coronary Intervention Versus Balloon Angioplasty for Multivessel Coronary Artery Disease
Contemporary Percutaneous Coronary Intervention Versus Balloon Angioplasty for Multivessel Coronary Artery Disease A Comparison of the National Heart, Lung and Blood Institute Dynamic Registry and the
More informationNova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Antiplatelet Section of the Guidelines)
Cardiovascular Health Nova Scotia Guideline Update Nova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Antiplatelet Section of the Guidelines) Authors: Dr. M. Love, Dr. I. Bata, K. Harrigan
More informationBelinda Green, Cardiologist, SDHB, 2016
Acute Coronary syndromes All STEMI ALL Non STEMI Unstable angina Belinda Green, Cardiologist, SDHB, 2016 Thrombus in proximal LAD Underlying pathophysiology Be very afraid for your patient Wellens
More informationThe New England Journal of Medicine
The New England Journal of Medicine Copyright, 1997, by the Massachusetts Medical Society VOLUME 336 A PRIL 3, 1997 NUMBER 14 INFLAMMATION, ASPIRIN, AND THE RISK OF CARDIOVASCULAR DISEASE IN APPARENTLY
More informationRelationship between body mass index, coronary disease extension and clinical outcomes in patients with acute coronary syndrome
Relationship between body mass index, coronary disease extension and clinical outcomes in patients with acute coronary syndrome Helder Dores, Luís Bronze Carvalho, Ingrid Rosário, Sílvio Leal, Maria João
More informationDownloaded from ismj.bpums.ac.ir at 4: on Monday January 7th (In-Stent Restenosis) :
- ( ) - *. (In-Stent Restenosis) :.. : ( ) :.. (hscrp) C.( ) : ) HDL ). ( ) :. HDL-C. C : / : - : Email :f.nekooei@gmail.com * / / (SAA) A (CRP).( ) CRP.(
More informationThe beneficial effect of high loading dose of rosuvastatin before percutaneous coronary intervention in patients with acute coronary syndrome
International Journal of Cardiology 137 (2009) 246 251 www.elsevier.com/locate/ijcard The beneficial effect of high loading dose of rosuvastatin before percutaneous coronary intervention in patients with
More informationA Normal Reference Coronary Flow Reserve is Associated With a Lower Mortality in Patients With Stable Coronary Artery Disease
A Normal Reference Coronary Flow Reserve is Associated With a Lower Mortality in Patients With Stable Coronary Artery Disease Tim van de Hoef, M.D. Steven AJ Chamuleau 2, Michiel Voskuil 2, Niels van Royen
More informationEXPERIMENTAL AND THERAPEUTIC MEDICINE 6: , 2013
840 Identification of independent risk factors for restenosis following bare metal stent implantation: Role of bare metal stents in the era of drug eluting stents CHANG BUM PARK 1 and HOON KI PARK 2 1
More informationAre We Making Progress With Percutaneous Saphenous Vein Graft Treatment? A Comparison of 1990 to 1994 and 1995 to 1998 Results
Journal of the American College of Cardiology Vol. 38, No. 1, 2001 2001 by the American College of Cardiology ISSN 0735-1097/01/$20.00 Published by Elsevier Science Inc. PII S0735-1097(01)01324-9 Are We
More information